Jennison Associates LLC Purchases 64,183 Shares of argenx SE (NASDAQ:ARGX)

Jennison Associates LLC raised its stake in argenx SE (NASDAQ:ARGX - Free Report) by 27.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 302,149 shares of the company's stock after purchasing an additional 64,183 shares during the period. Jennison Associates LLC owned 0.50% of argenx worth $185,821,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ARGX. SG Americas Securities LLC grew its holdings in shares of argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after buying an additional 21 shares during the last quarter. Raymond James Trust N.A. grew its holdings in shares of argenx by 6.0% during the third quarter. Raymond James Trust N.A. now owns 495 shares of the company's stock valued at $268,000 after buying an additional 28 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in argenx by 8.9% during the third quarter. Hantz Financial Services Inc. now owns 528 shares of the company's stock worth $286,000 after purchasing an additional 43 shares during the last quarter. Aaron Wealth Advisors LLC boosted its holdings in argenx by 10.1% during the fourth quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company's stock worth $301,000 after purchasing an additional 45 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in argenx by 47.5% during the third quarter. GAMMA Investing LLC now owns 174 shares of the company's stock worth $94,000 after purchasing an additional 56 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Trading Down 2.0 %

Shares of NASDAQ ARGX traded down $13.77 during midday trading on Thursday, hitting $657.97. The company's stock had a trading volume of 157,446 shares, compared to its average volume of 279,231. The stock has a fifty day moving average price of $636.51 and a 200 day moving average price of $574.93. argenx SE has a one year low of $349.86 and a one year high of $678.21. The firm has a market capitalization of $39.98 billion, a price-to-earnings ratio of -747.69 and a beta of 0.58.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Raymond James restated a "strong-buy" rating and set a $605.00 price target on shares of argenx in a report on Thursday, October 10th. William Blair upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a report on Friday, November 1st. Piper Sandler boosted their price target on shares of argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a report on Tuesday, January 7th. Scotiabank upgraded shares of argenx from a "sector perform" rating to a "sector outperform" rating and boosted their price target for the stock from $439.00 to $715.00 in a report on Tuesday, November 5th. Finally, Evercore ISI boosted their price target on shares of argenx from $675.00 to $706.00 and gave the stock an "outperform" rating in a report on Thursday, November 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $658.39.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.